Press release content from Business Wire. The AP news staff was not involved in its creation.

Bausch + Lomb and Glaucoma Research Foundation Announce Launch of Screen, Protect, Cure Campaign In Recognition of Glaucoma Awareness Month

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
January 3, 2023 GMT

VAUGHAN, Ontario--(BUSINESS WIRE)--Jan 3, 2023--

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, and Glaucoma Research Foundation (GRF), a national non-profit organization with the vision of curing glaucoma, today announced the U.S. launch of ’ Screen, Protect, Cure,’ a campaign designed to provide educational resources and raise awareness of glaucoma, a leading cause of irreversible blindness, during Glaucoma Awareness Month. 1

“We are proud to collaborate with Glaucoma Research Foundation to provide critical information about this serious eye disease and underline the negative toll it can have if left untreated,” said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb. “Glaucoma can affect individuals of all ages and only half of those affected are aware they have it, so it’s important that we share risk factors, how to get tested and what treatment options are available. Through ‘Screen, Protect, Cure,’ we hope to help support patients in every step of their treatment journey.” 1

During the month of January, Glaucoma Awareness Month, Bausch + Lomb and GRF will share educational resources to educate individuals who may be at risk for glaucoma and empower them to take an informed and active role in their eye health. The campaign also features a fundraising challenge that will match every dollar raised up to $20,000 in support of GRF research for a potential cure for glaucoma.

“Glaucoma Awareness Month provides a great opportunity to share information about this sight-threatening disease and remind people there are steps they can take to help preserve their vision,” said Thomas M. Brunner, president & CEO, GRF. “Visiting an eye care provider on an annual basis and paying attention to visual function are the best things someone can do to avoid the irreversible damage from glaucoma. Although there is currently no cure, our fight to prevent visual disability is ongoing, and we are grateful for the collaboration of organizations, such as Bausch + Lomb, who share this commitment with us.”

People interested in participating in the fundraising challenge or testing their knowledge about glaucoma can take an interactive quiz and learn more at glaucoma.org/screen-protect-cure.

About Glaucoma
Glaucoma is a complex, progressive disease that occurs when excessive eye pressure or other causes lead to damage of the optic nerve. The optic nerve is responsible for the communication of information between the eye and brain. Damage to the optic nerve can lead to severe vision loss, and in the worst case, blindness. As one of the leading causes of preventable blindness, glaucoma affects about three million people in the United States, but if caught early, it is possible to help slow and potentially prevent vision loss. 1,2

About Glaucoma Research Foundation
Founded in 1978, GRF is focused on its mission to cure glaucoma through innovative research, leading the industry as a nonprofit organization. Building teams of collaborating researchers and scientists over the years, all sharing the common goal of finding a cure – GRF is committed to raising awareness, spreading the word and encouraging others to achieve this shared goal. For more information visit, https://www.glaucoma.org/, and follow them on Facebook, Instagram, LinkedIn, and Twitter.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with more than 12,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Twitter, LinkedIn, Facebook and Instagram.

Forward-looking Statements
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch + Lomb, including but not limited to its project development timelines, launches and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.

References

®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates.
All other product/brand names and/or logos are trademarks of the respective owners.
© 2023 Bausch & Lomb Incorporated or its affiliates.
UBL.0055.USA.22

View source version on businesswire.com:https://www.businesswire.com/news/home/20230103005012/en/

CONTACT: Investor

Arthur Shannon

arthur.shannon@bausch.comAllison Ryan

allison.ryan@bausch.com

(877) 354-3705 (toll free)

(908) 927-0735Media:

Lainie Keller

lainie.keller@bausch.com

(908) 927-1198Kristy Marks

kristy.marks@bausch.com

(908) 927-0683

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: HEALTH OPTICAL

SOURCE: Bausch + Lomb Corporation

Copyright Business Wire 2023.

PUB: 01/03/2023 07:00 AM/DISC: 01/03/2023 07:02 AM

http://www.businesswire.com/news/home/20230103005012/en